Apellis Pharmaceuticals (APLS) EBT (2020 - 2025)
Historic EBT for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $216.3 million.
- Apellis Pharmaceuticals' EBT rose 48048.48% to $216.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.7 million, marking a year-over-year increase of 11883.8%. This contributed to the annual value of -$196.7 million for FY2024, which is 6263.68% up from last year.
- According to the latest figures from Q3 2025, Apellis Pharmaceuticals' EBT is $216.3 million, which was up 48048.48% from -$41.7 million recorded in Q2 2025.
- In the past 5 years, Apellis Pharmaceuticals' EBT ranged from a high of $216.3 million in Q3 2025 and a low of -$219.2 million during Q2 2021
- In the last 5 years, Apellis Pharmaceuticals' EBT had a median value of -$137.7 million in 2022 and averaged -$107.3 million.
- As far as peak fluctuations go, Apellis Pharmaceuticals' EBT plummeted by 22226.69% in 2021, and later soared by 48048.48% in 2025.
- Apellis Pharmaceuticals' EBT (Quarter) stood at -$147.6 million in 2021, then decreased by 13.47% to -$167.5 million in 2022, then soared by 47.96% to -$87.2 million in 2023, then soared by 58.62% to -$36.1 million in 2024, then surged by 699.76% to $216.3 million in 2025.
- Its EBT was $216.3 million in Q3 2025, compared to -$41.7 million in Q2 2025 and -$91.9 million in Q1 2025.